Lepu Biopharma (2157) Stock Overview
A biopharmaceutical company, focuses on the discovery, development, and commercialization of drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
2157 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Lepu Biopharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.93 |
| 52 Week High | HK$10.50 |
| 52 Week Low | HK$3.55 |
| Beta | -0.44 |
| 1 Month Change | -18.13% |
| 3 Month Change | -20.12% |
| 1 Year Change | -33.61% |
| 3 Year Change | -34.93% |
| 5 Year Change | n/a |
| Change since IPO | -44.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2157 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 2.6% | 0.1% | 0.2% |
| 1Y | -33.6% | -9.6% | 5.5% |
Return vs Industry: 2157 underperformed the Hong Kong Biotechs industry which returned -9.6% over the past year.
Return vs Market: 2157 underperformed the Hong Kong Market which returned 5.5% over the past year.
Price Volatility
| 2157 volatility | |
|---|---|
| 2157 Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 16.0% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 2157 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2157's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 710 | Ziye Sui | www.lepubiopharma.com |
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of MSI-H/dMMR solid tumors solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; CMG901 CLDN18.2-targeted ADC, which is in phase III trials for treating gastric and gastroesophageal junction carcinoma and other solid tumors; and MRG004A TF-targeted ADC, which is in phase III clinical trial for treating pancreatic ductal adenocarcinoma.
Lepu Biopharma Co., Ltd. Fundamentals Summary
| 2157 fundamental statistics | |
|---|---|
| Market cap | HK$7.09b |
| Earnings (TTM) | HK$302.85m |
| Revenue (TTM) | HK$1.08b |
Is 2157 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2157 income statement (TTM) | |
|---|---|
| Revenue | CN¥934.87m |
| Cost of Revenue | CN¥89.59m |
| Gross Profit | CN¥845.28m |
| Other Expenses | CN¥583.91m |
| Earnings | CN¥261.36m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 90.42% |
| Net Profit Margin | 27.96% |
| Debt/Equity Ratio | 75.7% |
How did 2157 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/13 07:04 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lepu Biopharma Co., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lu Meng | Haitong International Research Limited |
| Hanyang Huang | Industrial Securities Co. Ltd. |
| Sean Wu | Morgan Stanley |